Rchr
J-GLOBAL ID：202001021101351428
Update date: Dec. 03, 2024 Hiramoto Takafumi
Hiramoto Takafumi
- 2021 - 2024 新規修飾法による中和抗体に排除されないAAVベクターの開発と安全性の検討
- 2019 - 2021 Establishing of new AAV vector system against neutral antibody
- 2014 - 2015 疾患研究応用に向けたヒトiPS細胞からの高効率B細胞誘導法の開発
-
Tomoki Togashi, Nemekhbayar Baatartsogt, Yasumitsu Nagao, Yuji Kashiwakura, Morisada Hayakawa, Takafumi Hiramoto, Takayuki Fujiwara, Eriko Morishita, Osamu Nureki, Tsukasa Ohmori. Cure of Congenital Purpura Fulminans via Expression of Engineered Protein C Through Neonatal Genome Editing in Mice. Arteriosclerosis, thrombosis, and vascular biology. 2024. 44. 12. 2616-2627
-
Takafumi Hiramoto, Hiroshi Inaba, Nemekhbayar Baatartsogt, Yuji Kashiwakura, Morisada Hayakawa, Nobuhiko Kamoshita, Hiroshi Nishimasu, Osamu Nureki, Ei Kinai, Tsukasa Ohmori. Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A. Blood advances. 2023. 7. 22. 7017-7027
-
Tomohiro Hino, Satoshi N Omura, Ryoya Nakagawa, Tomoki Togashi, Satoru N Takeda, Takafumi Hiramoto, Satoshi Tasaka, Hisato Hirano, Takeshi Tokuyama, Hideki Uosaki, et al. An AsCas12f-based compact genome-editing tool derived by deep mutational scanning and structural analysis. Cell. 2023
-
Yuji Kashiwakura, Kazuhiro Endo, Atsushi Ugajin, Tomohiro Kikuchi, Shuji Hishikawa, Hitoyasu Nakamura, Yuko Katakai, Nemekhbayar Baatartsogt, Takafumi Hiramoto, Morisada Hayakawa, et al. Efficient Gene Transduction in Pigs and Macaques with the Engineered AAV Vector AAV.GT5 for Hemophilia B Gene Therapy. Molecular Therapy - Methods & Clinical Development. 2023. 30. 502-514
-
冨樫 朋貴, ネメフバヤル・バータルツォグト, 長尾 恭光, 柏倉 裕志, 早川 盛禎, 鴨下 信彦, 平本 貴史, 藤原 隆行, 森下 英理子, 濡木 理, et al. 改変型プロテインCによるプロテインC欠損マウスのゲノム編集治療. 日本血栓止血学会誌. 2023. 34. 2. 257-257
ｍore...-
Jiyuan Liao, Yasushi Soda, Ai Sugawara, Yoshie Miura, Takafumi Hiramoto, Maino Tahara, Yuto Takishima, Shohei Miyamoto, Makoto Takeda, Kenzaburo Tani. Non-Integrating Measles Virus Vector is a Promising Tool for Naive iPSCs Generation and T-cell Engineering. MOLECULAR THERAPY. 2020. 28. 4. 531-531
-
Jiyuan Liao, Yasushi Soda, Ai Sugawara, Yoshie Miura, Takafumi Hiramoto, Maino Tahara, Yuto Takishima, Shohei Miyamoto, Makoto Takeda, Kenzaburo Tani. F-Deletion Non-Integrating Measles Virus Vector: A Promising Tool for T-Cell Engineering and Naive iPSCs Generation. BLOOD. 2019. 134
-
Jiyuan Liao, Yasushi Soda, Ai Sugawara, Yoshie Miura, Takafumi Hiramoto, Maino Tahara, Yuto Takishima, Yasuki Hijikata, Shohei Miyamoto, Makoto Takeda, et al. Analysis of Human iPSCs Generated by a Non-Integrating Measles Virus Vector. MOLECULAR THERAPY. 2019. 27. 4. 418-418
-
Takafumi Hiramoto, Maino Tahara, Chika Sakamoto, Hiroaki Ono, Hiroshi Kohara, Makoto Takeda, Kenzaburo Tani. Non-Transmissible Measles Virus Vector Selectively Induces Human Primed and Naive like Pluripotent Stem Cells from Hematopoietic Cells. BLOOD. 2015. 126. 23
-
Takafumi Hiramoto, Maino Tahara, Chika Sakamoto, Yuichiro Nakatsu, Toru Kubota, Hiroaki Ono, Hiroshi Kohara, Makoto Takeda, Kenzaburo Tani. Newly Developed Measles Virus Vector Can Simultaneously Transfer Multiple Genes Into Human Hematopoietic Cells and Induce Ground State Like Pluripotent Stem Cells. MOLECULAR THERAPY. 2015. 23. S2-S3
ｍore...- ゲノム編集技術を応用した製品開発とその実用化
技術情報協会 2021 ISBN:9784861048272
- 医学のあゆみ ゲノム編集の未来
2020
- いま、本格化する遺伝子治療 : 遺伝性疾患・がんと戦う新たな一手
羊土社 2020 ISBN:9784758103848
- Pharma Medica 血友病診断の新たな展望
2019
-
遺伝子改変Cas9を用いた塩基編集による血友病B患者由来iPS細胞の原因遺伝子修復
(2020)
-
Correction of human haemophilia B gene in iPSCs by base-editing approach based on engineered Cas with broad PAM flexibility
(International Society on Thrombosis and Haemostasis Annual Meeting)
-
塩基編集による血友病B患者由来iPSC の遺伝子修復
-
THERAPEUTIC GENE CORRECTION OF HUMAN HEMOPHILIA B IPSCS BY BASE-EDITING APPROACH BASED ON AN ENGINEERED CAS9 WITH BROAD PAM FLWXIBILITY.
(Frontiers in Genome Engineering.)
-
Nuclease-free adeno-associated virus-mediated Il2rg gene editing in X-SCID mice.
ｍore...- 2023/04 - 現在 Dokkyo Medical University
